Car-expressing cells against multiple tumor antigens and uses thereof
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsCarl H. June, Daniel J. Powell, JR.
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
Claims47
An isolated nucleic acid, comprising:
- (a) a nucleotide sequence encoding an agent, wherein the agent is a polypeptide or nucleic acid that enhances the immune response against a target cell or a cancer cell, wherein the agent is chosen from a chimeric antigen receptor (first CAR), an inhibitor of a checkpoint inhibitor, or a cytokine;
- and
- (b) a first activation-conditional control region operatively linked to (a).
An isolated nucleic acid comprising:
- (a) a nucleotide sequence encoding an agent, wherein the agent is a polypeptide or nucleic acid that enhances the immune response against a target cell, or a cancer cell, and wherein the agent is chosen from a chimeric antigen receptor (first CAR), an inhibitor of a checkpoint inhibitor, or a cytokine, wherein the first CAR comprises a first an antigen binding domain, a transmembrane domain, and an intracellular signaling domain;
- (b) a first activation-conditional control region operatively linked to (a);
- (c) a nucleotide sequence encoding a second CAR comprising a second antigen binding domain, a transmembrane domain, and an intracellular signaling domain;
- and
- (d) a second control region operatively linked to (c), wherein the second control region is other than an activation-conditional control region and wherein the second control region comprises a constitutive control region.
(canceled)
-13. (canceled)
-16. (canceled)
-22. (canceled)
(canceled)
(canceled)
(canceled)
-32. (canceled)
(canceled)
(canceled)
-43. (canceled)
-49. (canceled)
-53. (canceled)
-62. (canceled)
-68. (canceled)
-74. (canceled)
-82. (canceled)
-85. (canceled)
-91. (canceled)
-94. (canceled)
Dependencies are inferred from the claim text.